GeneHarbor Holding incorporated in Bermuda in 2004, focuses on the design and development of innovative enzymes and their manufacture and the commercial application in various industries. GeneHarbor is currently one of a few companies in the world that has a complete chain of enzymatic production with advanced technology in each of the manufacturing steps. At present, three major obstacles prevent the enzymatic process from wider industrial applications (1) high cost of the enzymes; (2) high cost of the coenzyme (ATP, NADH, NADPH, etc); and (3) lack of robust process tailored for industrial production. We at GeneHarbor have committed nearly 20 years of intensive R&D to address the above challenges. We have developed a series of platform technologies that significantly reduce the cost of the enzymes and coenzymes required and make the enzymatic manufacture of many biochemicals possible. We have, at industrial scale, established commercial viable production of glutathione (GSH); S-adenosylmethione (SAMe); Nicotinamide adenine dinucleotide (NAD) and Nicotinamide mononucleotide (NMN). We believe that GH’s technology is now ready for low cost production of highest quality of many more complicated biochemicals. GeneHarbor has collaboration with a number of leaders in the pharmaceutical and nutritional industries to apply GeneHarbor’s proprietary technologies for industrial production of high-value added products. GeneHarbor, a Hong Kong Science and Technology Parks Corporation (HKSTP) partner company since 2007, has its pilot manufacture facility in Shanghai, and large manufacture factories in Suzhou and Ningbo. We have established our first shop of consumer products in 2018. Address: Shop S003A, Core Building 1, No 1, Science Park East Avenue, HK Science Park, Shatin, N.T., HONG KONG.